US FDA expands Breyanzi use for aggressive mantle cell lymphoma, marking third approval this year.
The US FDA has expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi (lisocabtagene maraleucel), to treat an aggressive and rare form of blood cancer, mantle cell lymphoma (MCL). This marks the third approval for Breyanzi this year. The approval is based on data from a study that showed Breyanzi helped clear all signs of cancer in 67.6% of MCL patients who had previously received two or more treatments. Breyanzi belongs to the class of CAR-T treatments and works by modifying white blood cells, or T-cells, to attack cancer.
May 30, 2024
8 Articles